Each ml contains
Butylscopolamine bromide 4 mg
Metamizole 500 mg
Butylscopolamine bromide is a spasmolytic agent with particular activity on the smooth muscle of the digestive and urinary systems. It antagonises the actions of acetylcholine at the muscarinic receptor and also has some activity at nicotinic receptors. Its pharmacological profile is similar to atropine, the main member of this class.
Metamizole is a non-steroidal anti-inflammatory drug of the pyrazolone group and also has analgesic and anti-pyretic effects.
Horses and dogs
Horses : 25 mg Metamizole per kg body weight, 0.2 mg Butylscopolamine bromide per kg body weight
Dogs : 50 mg Metamizole per kg body weight, 0.4 mg Butylscopolamine bromide per kg body weight
Horses: 5 ml per 100 kg body weight by intravenous or intramuscular injection
Dogs: 0.1 ml per kg body weight by intravenous or intramuscular injection
Studies in laboratory animals (rabbit, rat) have not produced any evidence of a teratogenic effect.
No information on use during pregnancy in the target species is available and therefore this product should not be used.
Lead to a decrease in mononucleosis (AGRANULOCYTOSIS )
In horses, a slight transient increase in heart rate may be observed due to the parasympatholytic activity of butylscopolaminiumbromide (hyoscine butylbromide).
None
Store in dry dark and place at temperature not exceeding to 30 o.
Vial of 50,100 and 250 ml